The EMJ Podcast | Bonus Episode
Dr Teresa Amaral and Prof Mario Mandalà discuss: The typical patient for whom adjuvant therapy may be considered, and provide details on therapy choices. The long-term advantages of adjuvant treatments, and prospects for the use of biomarkers to help elucidate the best candidates for such therapies. The potential disadvantages of adjuvant therapy, and how more studies are needed to understand if these therapies can impact quality of life and fertility.
Spotify | Apple | Amazon Music | Download MP3 (31:51 mins)
This content was fully funded by Novartis Pharma AG
Speakers
Teresa Amaral
Skin Cancer Clinical Trials Center, Eberhard Karls University of Tübingen, Germany
Mario Mandalà
Università degli Studi di Perugia, Italy
Dr Teresa Amaral and Prof Mario Mandalà discuss:
- The typical patient for whom adjuvant therapy may be considered, and provide details on therapy choices.
- The long-term advantages of adjuvant treatments, and prospects for the use of biomarkers to help elucidate the best candidates for such therapies.
- The potential disadvantages of adjuvant therapy, and how more studies are needed to understand if these therapies can impact quality of life and fertility.
Read more from the ‘Adjuvant Melanoma Treatment’ series: EMJ Dermatology 12 [Supplement 1] 2024 – European Medical Journal (emjreviews.com)
